BRCA and CDK4/6: allies or antagonists?-efficacy of CDK4/6 inhibitors in HR+/HER2- breast cancer with germline BRCA1/2 mutations: a narrative review
{{output}}
Background and objective: Breast cancer (BC) remains the most prevalent malignancy in women globally, with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) tumors representing approximatel... ...
